Constitutive androstane receptor CAR (NR1I3) has been identified as a central mediator of coordinate responses to xenobiotic and endobiotic stress. Here we use leptin-deficient mice (ob/ob) and ob/ob, CAR ؊/؊ double mutant mice to identify a metabolic role of CAR in type 2 diabetes. Activation of CAR significantly reduces serum glucose levels and improves glucose tolerance and insulin sensitivity. Gene expression analyses and hyperinsulinemic euglycemic clamp results suggest that CAR activation ameliorates hyperglycemia by suppressing glucose production and stimulating glucose uptake and usage in the liver. In addition, CAR activation dramatically improves fatty liver by both inhibition of hepatic lipogenesis and induction of ␤-oxidation. We conclude that CAR activation improves type 2 diabetes, and that these actions of CAR suggest therapeutic approaches to the disease.
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insulin resistance ͉ nuclear receptor ͉ xenobiotics T ype 2 diabetes mellitus (T2D) is primarily characterized by insulin resistance and leads to uncontrolled glucose and lipid metabolism (1, 2) . In diabetic subjects, the major insulinresistant organs are liver, muscle, and adipose tissue. Liver is the major organ for endogenous glucose production and lipogenesis, both of which are tightly controlled by various metabolic and nutritional factors (3) . Diabetic liver is unresponsive to insulin suppression of glucose output, but continues to produce large amounts of lipids. Hepatic overproduction of glucose and fatty acids further impairs insulin signaling thereby establishing a vicious cycle (4, 5) . Liver is also a principal organ of drug metabolism, which depends on a variety of phase I oxidizing enzymes, primarily cytochrome P450's (CYPs) with broad substrate specificities, as well as phase II conjugating enzymes and phase III transporters (6) . CAR (constitutive androstane receptor) and PXR (pregame X receptor) constitute two essential members of the nuclear receptor family. They function as sensors of toxic derivatives from xenobiotic and endobiotic metabolism. In general, CAR appears to be more essential in response to endogenous stimuli, while PXR appears to act primarily in xenobiotic induction of drug metabolism. Highly expressed in the liver, CAR is activated by phenobarbital (PB) and a group of structurally diverse agents referred to as ''phenobarbital like,'' such as TCPOBOP (TC) (7) .
A link between drug metabolism and diabetes was suggested by reports that PB treatment decreases plasma glucose and improves insulin sensitivity, not only in a diabetic rodent model (8) , but also in human T2D patients (9) . Moreover, treatments with CAR activators PB and TC repress the expression of the hepatic gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P) in mouse liver (10) and rat hepatocytes (11) . Recently, this effect has been attributed to the inhibitory effect of CAR on insulin dependent activity of FOXO1 (12) .
We used ob/ob and ob/ob CAR Ϫ/Ϫ double mutant mice to investigate the role of CAR in T2D. Our results show that the antidiabetic effects of the more specific CAR agonist TCPOBOP (TC) are lost in the double mutant mice, and that activation of CAR significantly affects both glucose and lipid homeostasis. In particular, CAR activation represses gluconeogenesis, while increasing hepatic glucose uptake and utilization. It also represses lipogenic gene expression via a mechanism dependent at least in part on inactivation of oxysterol ligands for the liver X receptors LXR␣ and ␤, and increases ␤-oxidation via an unexpected pathway associated with decreased expression of acetylCoA carboxylase 2 (ACC2).
Results
CAR Activation Improves Glucose Metabolism in ob/ob Mice. To study the role of CAR in T2D, we crossed the CAR Ϫ/Ϫ allele into the ob/ob background to generate double mutant mice (ob/ob, CAR Ϫ/Ϫ ). Loss of CAR function in the ob/ob background had no effect on a number of parameters, including body weight, food intake, fat-to-body weight ratio, and serum levels of triglycerides, cholesterol, and free fatty acids (Fig. S1 A-F) . The lack of effect on serum triglycerides contrasts with a recent report using ob/ob, CAR Ϫ/Ϫ mice generated using a distinct CAR Ϫ/Ϫ allele (13) . In that study, the effect on serum triglycerides was attributed to an activation of PPAR␣, which we did not observe in our ob/ob, CAR Ϫ/Ϫ mice ( Fig. S1 G and H) . We conclude that our ablation of CAR in the ob/ob background does not affect the obese phenotype.
To test whether diabetes and obesity affect CAR activity, 10-week-old ob/ob and ob/ob CAR Ϫ/Ϫ mice were treated with the CAR specific agonist TCPOBOP (TC) for a week. As expected, expression of CAR targets Cyp2B10 and Cyp3A11 were robustly elevated in the TC-treated ob/ob mice, but not in the ob/ob, CAR Ϫ/Ϫ mice or vehicle treated ob/ob mice. Thus, the ob/ob background has no apparent effect on either the basal activity or the agonist response of CAR (Fig. S2) .
To initially investigate how CAR influences glucose metabolism, we monitored glucose levels in ob/ob and ob/ob, CAR Ϫ/Ϫ mice in response to an acute 1-week TC treatment. Serum glucose levels were significantly decreased in TC-treated ob/ob, but not ob/ob, CAR Ϫ/Ϫ mice (Fig. 1A) . In i.p. glucose tolerance tests (GTT), TC-treated ob/ob mice displayed significantly improved glucose tolerance compared with control treated ob/ob mice, as shown by reduced blood glucose levels at each time point, and this effect was also completely absent in the double mutant ob/ob CAR Ϫ/Ϫ mice (Fig. 1B) . The decreased serum glucose levels were associated with appropriately decreased serum insulin levels, indicating that CAR activation alleviates hyperinsulinemia in the ob/ob mice and improves glucose tolerance (Fig. 1C) .
Since T2D is a chronic disease, we examined the effects of long-term CAR activation. This longer term treatment also minimizes the impact of the CAR-dependent hepatomegaly that occurs over the first week of treatment. Starting at 6 weeks of age, ob/ob and ob/ob, CAR Ϫ/Ϫ mice were treated with one dose of TC per week for 1 month. ob/ob mice gradually develop T2D over this time course, as revealed by markedly elevated serum glucose in the vehicle treated ob/ob group (Fig. S3) . TC treatment significantly attenuated this diabetes progression in ob/ob mice, but not in ob/ob, CAR Ϫ/Ϫ mice ( Fig. S3 A and B) . The TC-treated ob/ob mice showed a dramatic improvement in the GTT, which was not observed in the ob/ob, CAR Ϫ/Ϫ mice ( Fig. 2A) . To critically determine whether CAR activation improves insulin sensitivity, 1-month TC-treated or control ob/ob mice were studied using the hyperinsulinemic euglycemic clamp. TC treatment resulted in a dramatic 3-fold increase in glucose infusion rate (GIR), demonstrating markedly improved insulin sensitivity (Fig. 2CII ). TC treatment also strongly repressed both the basal glucose production and hepatic glucose production ( Fig. 2 CI and CIII) . The difference in GIR can be mostly attributed to the insulin-induced reduction of hepatic glucose production because peripheral glucose uptake remains the same in both groups (Fig. 2CIV ). These results suggest that activation of CAR improves liver insulin sensitivity mainly through suppression of de novo glucose production.
To rule out concerns related to the potential impact of the absence of leptin signaling in the ob/ob mice, we studied the effect of CAR activation in the diet induced obesity model of insulin resistance. Wild-type and CAR Ϫ/Ϫ mice were fed with a high-fat diet (45% of calories) for 2 months and treated with vehicle or TC for another month while maintaining the same diet. Consistent with the ob/ob results, TC treatment significantly improved glucose tolerance in wild-type mice, but not in the CAR Ϫ/Ϫ mice (Fig. 2D ).
CAR Regulates Glucose Metabolic Genes. Both the reduced fasting serum glucose level and decreased hepatic glucose production during the clamp in the TC-treated ob/ob mice indicate that gluconeogenesis is strongly suppressed by CAR activation. Consistent with previous studies in lean mice (12, 14) , we found that expression of the gluconeogenic genes PEPCK and G-6-Pase (G6P) was repressed by TC treatment in the ob/ob mice, but not in the ob/ob, CAR Ϫ/Ϫ double mice (Fig. 3) . Previous studies have shown that phenobarbital treatment increases glucose uptake and utilization in the liver of ob/ob mice, as indicated by increased activity of key enzymes such as hexokinase (HK) and phosphogluconate dehydrogenase (PGD) (9, 15) . Hexokinases catalyze glucose phosphorylation, the essentially irreversible first step of the glycolytic pathway (16) . In accord with the previous studies of enzymatic activities, CAR activation induces hexokinase mRNA (Fig. 3 ), but does not affect glucokinase gene expression. PGD, the rate-limiting enzyme in the pentose phosphate pathway, is also induced by approximately 2-fold in the TC-treated ob/ob mice but not in the ob/ob, CAR Ϫ/Ϫ double mutant mice (Fig. 3) . As expected, the responses of these genes to CAR activation in high-fat-diet-fed mice were similar to those observed in the ob/ob mice (Fig. S4) . In transient transfections with proximal promoter constructs, CAR was able to transactivate the hexokinase promoter and, to a lesser extent, the PGD promoter, indicating that both genes are primary CAR targets (Fig. S5) . Overall, we conclude that CAR regulates glucose homeostasis by suppressing gluconeogenesis and inducing glucose uptake and consumption in the liver.
CAR Activation Improves Fatty Liver in ob/ob Mice. Fatty liver disease is highly associated with T2D. To determine the effect of CAR activation on hepatic fat accumulation, liver samples from 1-month control and TC-treated ob/ob mice were examined for histology and lipid content. TC treatment significantly improved fatty liver histology and decreased hepatic triglycerides in ob/ob mice, and these responses were absent in the ob/ob, CAR Ϫ/Ϫ mice ( Fig. 4 A and B and Fig. S6 ).
Reduced hepatic lipid content can be due to decreased de novo hepatic lipogenesis or increased fatty acid ␤-oxidation. We first examined expression of lipogenic genes in response to 1-month TC treatment. Compared to vehicle treated ob/ob mice, TC-treated ob/ob mice showed significant repression of not only SREBP-1c mRNA, but also its downstream genes, such as FAS and SCD-1 (Fig. 4C) . Again, these responses were absent in the double mutant ob/ob CAR Ϫ/Ϫ mice. These results are consistent with the previous demonstration that TC treatment decreases SREBP-1c protein levels (17) , and strongly suggest that CAR activation suppresses lipogenesis.
Liver SREBP-1c is regulated by insulin through liver X receptor (LXR) signaling (18, 19) . Cholesterol sulfotransferase 2B1b (SULT2B1b) attenuates LXR signaling by sulfating and inactivating oxysterol agonist ligands (20) . Sulfotransferases, like other phase II drug metabolism enzymes, are potential CAR targets (7, 21) , and CAR activation does induce SULT2B1b expression (Fig. 5A) . We used SULT2B1b null mice to test the relevance of this induction for the effect of TC on SREBP-1c expression. As expected, CAR induction of Cyp2B10 expression was unaltered in the SULT2B1b null mice, and repression of PEPCK expression was also unaffected (Fig. S7A) . TC repression of SREBP-1c expression was lost in the Sult2B1b knockout mice (Fig. 5B) , while the repression of SCD-1 expression was attenuated. Expression of the LXR target genes ABCG5 and ABCG8 was also suppressed by CAR activation (Fig. S7B) , confirming the suppression of LXR signaling. These results indicate that this indirect pathway of LXR ligand inactivation plays an important role in CAR suppression of lipogenesis, although other mechanisms are likely to contribute. We used a metabolomic approach to further characterize the physiological role of CAR in lipid metabolism. Comparing a series of metabolites in TC vs. control treated liver samples revealed a marked induction of acylcarnitines, essential intermediates in mitochondrial fatty acid import and ␤-oxidation, in ob/ob mice but not in ob/ob, CAR Ϫ/Ϫ mice (Fig. 6A) . Three important organic acids in the TCA cycle, fumarate, malate, and ␣-ketoglutarate, were also induced by CAR activation (Fig. 6A) . The absence of a similar response of pyruvate indicates that the induced TCA products are derived from increased ␤-oxidation, rather than from glycolysis. Consistent with this, serum ketone bodies, an indicator of increased ␤-oxidation, were increased by TC treatment in ob/ob mice, but not in ob/ob, CAR Ϫ/Ϫ mice (Fig.  6B) . ␤-oxidation was examined directly in primary hepatocytes from wild-type and CAR Ϫ/Ϫ mice treated with TC or vehicle for 3 days. As expected, [ 14 C]-palmitate oxidation was significantly increased by TC in the wild-type hepatocytes, whereas there were no differences in TC vs. control groups from CAR Ϫ/Ϫ mice (Fig. 6B) .
We examined expression of a number of genes related to key steps in ␤-oxidation, including PPAR␣, CPT-1, CPT-2, and different acyl-CoA dehydrogenases, but did not observe an obvious basis for this increase. However, ␤-oxidation is potently suppressed by malonyl-CoA, the initial committed product in lipogenesis and an allosteric inhibitor of the carnitine-dependent pathway of mitochondrial fatty acid import (22, 29) . Consistent with a report that ACC2 is a direct SREBP-1c target (23), we found that ACC2 and also ACC1 mRNA expression was significantly suppressed by CAR activation (Fig. 6C) . Thus, CAR activation could promote ␤-oxidation indirectly by suppressing malonyl-CoA production.
Discussion
Previous studies have shown beneficial effects of PB on insulin sensitivity in both mouse models (8) and human T2D patients (8, 9) , but the basis for these antidiabetic effects has been unclear. We used two complementary approaches to critically test the hypothesis that CAR mediates these effects. The first is the pharmacologic substitution of TC, a much more specific mouse CAR agonist that does not activate AMP kinase, for PB. The second is the genetic introduction of the CAR Ϫ/Ϫ allele into the ob/ob mouse model of obesity and T2D. TC induces antidiabetic effects very similar to those described for PB in the ob/ob model, and those effects are lost in the ob/ob, CAR Ϫ/Ϫ double mutants, definitively establishing CAR as the mediator of such antidiabetic effects. While this manuscript was in review, similar antidiabetic effects of TC were reported (24) . TC treatment decreased body weight in those studies, possibly due to toxic effects that do not occur in our mice. This decreased body weight could amplify the antidiabetic effect, but is clearly not essential for the TC activity that we observed or the previous results with PB, which also did not decrease body weight (8) .
Increased hepatic glucose production is a major contributor to hyperglycemia in T2D. The hyperinsulinemic euglycemic clamp studies show that CAR activation markedly improves insulin sensitivity and decreases hepatic glucose production in the ob/ob mice. In accord with this, and also with both earlier studies of PB effects on enzyme activities (8) and more recent studies (12, 14) , TC treatment suppresses expression of the key gluconeogenic genes PEPCK and G6P. CAR also induces important genes in glucose uptake (hexokinase), and also utilization via the pentose phosphate pathway (PGD), which supports drug metabolism by generating NADPH, an obligate cofactor for cytochrome P450 reductase. Outside of the context of the xenobiotic response, activation of the pentose phosphate shunt has also been sug- gested to contribute to the suppression of hyperglycemia by PPAR␦ activation (25) . Elevated liver triglycerides are tightly associated with insulin resistance and T2D, and PB treatment alleviates fatty liver in rodents (8, 26) , and possibly human T2D patients (27) . Our results with TC are also consistent with another recent study using the methionine and choline deficient diet to induce fatty liver (28) . We identified two mechanisms for the impact of CAR activation on hepatic steatosis: suppression of lipogenesis and induction of ␤-oxidation. TC treatment decreased expression of the lipogenic transcription factor SREBP-1c and its downstream genes. These responses are consistent with a recent report that TC treatment decreased nuclear levels of the mature SREBP-1c protein (17) .
Exploring the molecular basis for decreased SREBP-1c expression, we found that CAR induces the phase II enzyme SULT2B1b, which sulfates and inactivates oxysterol agonists for LXR, a well known activator of SREBP-1c expression. The suppressive effect of CAR activation on lipogenic gene expression is substantially impaired in SULT2B1b knockout mice. Thus, it is likely that this indirect pathway of LXR ligand inactivation contributes significantly to the decreased SREBP-1c expression, and that there are additional mechanisms, including the previously described induction of INSIG-1 as primary CAR target (17) .
While we observed a clear increase in hepatic ␤-oxidation, we did not find substantial effects of CAR activation on gene expression of key components of this pathway. However, our results are consistent with recent studies showing that PB treatment induces serum ketone bodies, indicating increased ␤-oxidation (30) , and that CAR activation induces enzymes involved in fatty acid microsomal omega-oxidation and peroxisomal ␤-oxidation (28) . Consistent with the decreased triglyceride accumulation in the TC-treated ob/ob livers, metabolomic profiling revealed markedly elevated levels of acylcarnitines and TCA cycle organic acids, suggesting increased ␤-oxidation. This was confirmed by observations that CAR activation results in elevated levels of serum ketone bodies and, more directly, increases palmitate oxidation in TC-treated hepatocytes.
Decreased levels of malonyl-CoA provide a plausible mechanism for this increase. Production of malonyl-CoA by ACC1 and ACC2 initiates lipogenesis, and strongly suppresses the opposing ␤-oxidation pathway by allosteric inhibition of CPT-1 enzymatic activity, which decreases fatty acid transport into mitochondria. Decreasing activity of ACC1 and particularly ACC2 has beneficial effects on both hepatic steatosis and insulin resistance (31) , and very similar effects are achieved by overexpression of malonyl CoA decarboxylase (32) . CAR activation significantly represses both ACC1 and ACC2 expression, strongly suggesting that CAR induces ␤-oxidation by decreasing malonyl CoA levels. Recent studies have shown that SCD-1 ablation protects against hepatic steatosis by the combined effects of decreased lipogenesis and increased ␤-oxidation (33). Hence, reduced SCD-1 expression by CAR activation may also contribute to this induced ␤-oxidation.
In summary, our results document the beneficial impact of specific CAR activation in T2D and fatty liver disease, and identify mechanisms that can account for such effects. PB is not used for treating T2D patients because of its undesirable side effects, such as promoting hepatocyte proliferation and increasing drug-to-drug interaction. As with other nuclear receptors, however, it may be possible to limit or even eliminate these problems using selective CAR modulators that retain beneficial effects on glucose and lipid metabolism, but not undesirable effects on drug metabolism and proliferation.
Experimental Procedures
Metabolic Studies. Glucose tolerance test was performed by i.p. injecting glucose (0.625g/kg for obese mice and 1.5g/kg for lean mice). Blood glucose was measured by tail bleeds at 0, 15, 30, 60, and 120 min post glucose dose. Hyperinsulinemic clamp (insulin dose is 15 mU/kg/min) was performed and calculated as described in our previous publication (34) . Acylcarnitines and organic acids were measured using stable isotope dilution techniques as previously described (35, 36) . Acylcarnitine species were measured using flow injection tandem mass spectrometry (MS/MS) and sample preparation methods described previously (37, 38) . Organic acids were quantified using a previously described method that utilizes Trace GC Ultra coupled to a Trace DSQ MS operating under Excalibur 1.4 (Thermo Fisher Scientific) (35) .
Gene Expression Analysis. Total RNA was extracted from mouse liver using TRIzol reagent (Invitrogen). Equivalent amounts of RNA from each treatment group were pooled, and 20 g was used for Northern blot analysis. The primers used for generation of each cDNA probe were described previously (39) . All of the blots were stripped and hybridized subsequently with the ␤-Actin probe as the internal control. For Q-PCR experiment, RNA was reversetranscribed by using SuperScript™ III RT (Invitrogen). Samples were run by using SYBR green (Applied Biosystems) and compared with levels of GAPDH as a control. Thermal cycling was carried out with an ABI prism 7500 sequence detection system (Applied Biosystems). Primers are purchased from Qiagen.
